Here are five takeaways:
1. Although the spine device market is hindered by costly procedures and pricing restrictions, the Zimmer Biomet-LDR transaction suggests there is opportunity in the space.
2. With its acquisition of LDR, Zimmer Biomet is positioning itself to be a dominant player in the spine device market.
3. This acquisition may, in turn, inspire other deals as companies try to compete.
4. LDR proved an attractive target as it develops the Mobi-C CDR device, which is the only FDA-approved device to treat one- and two-level cervical damaged discs.
5. Zimmer Biomet anticipates completing the $1 billion acquisition in the third quarter of 2016.
More articles on devices:
SI-BONE, Stryker, Centinel Spine & more: 19 key notes
Terry Rich, Wright Medical’s president of upper extremities, resigns: 3 takeaways
PONTiS Orthopaedics launches Achilles System — 4 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
